Manjunatha Panduranga Mudgal
Manjunatha Panduranga Mudgal has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Uday Raj Sharma
Department of Pharmacology Acharya & BM Reddy College of Pharmacy 560107 Bangalore India
4 shared publications- Gurubasavaraja Swamy Purawarga Matada
Integrated Drug Discovery Center Department of Pharmaceutical Chemistry Acharya & BM Reddy College of Pharmacy Bengaluru Karnataka India
3 shared publications Suresh Janadri
Department of Pharmacology Acharya & BM Reddy College of Pharmacy 560107 Bangalore India
3 shared publications- Uday Raj Sharma
Department of Pharmacology, Acharya & BM Reddy College of Pharmacy, Bengaluru, India
3 shared publications Haribabu T
2 shared publications- Madhu M V2 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 17 (4) , 101359
The systemic anti-diabetic effect of polyherbal formulation Varanadi Kashayam is mediated through GLP-1 secretion and DPP4 inhibition
- 9 July 2026
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 17 (4) , 101359
Open AccessThe systemic anti-diabetic effect of polyherbal formulation Varanadi Kashayam is mediated through GLP-1 secretion and DPP4 inhibition
- 28 August 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (5) , 1530-1545
Neratinib-loaded solid lipid nanoparticles in dissolvable microneedles for enhanced transdermal breast cancer therapy
Neratinib, an FDA-approved drug for breast cancer, faces challenges such as poor solubility, limited permeability, and adverse side effects. To address these issues, we developed dissolving microneedles incorporating Neratinib-loaded solid lipid nanoparticles (SLNs) to enhance transdermal delivery and minimize systemic toxicity. SLNs were formulated via hot homogenization using glyceryl monostearate as the lipid matrix and were evaluated for particle size, drug entrapment efficiency, drug loading, and stability. The optimized formulation (F7) exhibited a particle size of 209.4 nm and 87.57% entrapment efficiency. SLNs were integrated into microneedles using a micro-molding technique. Characterization included IR spectroscopy, scanning electron microscopy, mechanical strength, and insertion ability. Ex vivo studies on porcine skin demonstrated 80.71 ± 1.43% cumulative drug release over 24 h, confirming effective skin penetration. In vitro cytotoxicity on MCF-7 breast cancer cells showed greater efficacy of the SLN formulation over free Neratinib, with lower IC50 values (55.965 vs. 66.568 µg/mL), indicating enhanced cellular uptake and sustained release. The findings support dissolvable microneedles loaded with Neratinib-SLNs as a promising transdermal approach for targeted breast cancer therapy, offering improved bioavailability, reduced side effects, and better patient compliance.
- 28 August 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (5) , 1530-1545
Neratinib-loaded solid lipid nanoparticles in dissolvable microneedles for enhanced transdermal breast cancer therapy
Neratinib, an FDA-approved drug for breast cancer, faces challenges such as poor solubility, limited permeability, and adverse side effects. To address these issues, we developed dissolving microneedles incorporating Neratinib-loaded solid lipid nanoparticles (SLNs) to enhance transdermal delivery and minimize systemic toxicity. SLNs were formulated via hot homogenization using glyceryl monostearate as the lipid matrix and were evaluated for particle size, drug entrapment efficiency, drug loading, and stability. The optimized formulation (F7) exhibited a particle size of 209.4 nm and 87.57% entrapment efficiency. SLNs were integrated into microneedles using a micro-molding technique. Characterization included IR spectroscopy, scanning electron microscopy, mechanical strength, and insertion ability. Ex vivo studies on porcine skin demonstrated 80.71 ± 1.43% cumulative drug release over 24 h, confirming effective skin penetration. In vitro cytotoxicity on MCF-7 breast cancer cells showed greater efficacy of the SLN formulation over free Neratinib, with lower IC50 values (55.965 vs. 66.568 µg/mL), indicating enhanced cellular uptake and sustained release. The findings support dissolvable microneedles loaded with Neratinib-SLNs as a promising transdermal approach for targeted breast cancer therapy, offering improved bioavailability, reduced side effects, and better patient compliance.
- 3 April 2025
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (8) , 1399-1411
Design and formulation of fast-dissolving microneedles for the rapid transdermal delivery of lorazepam
This study investigates lorazepam-loaded dissolving microneedles (LMNs) as a fast-acting and minimally invasive treatment for status epilepticus. The LMNs were developed using a micro-moulding technique with an optimised combination of PVP K30, Dextran 40 and Pullulan. Their stability was confirmed through Fourier transform infra-red (FTIR) spectroscopy and X-ray diffraction (XRD) analysis. The Parafilm® membrane insertion test demonstrated 100% penetration efficiency, verifying their ability to effectively pierce the skin. Scanning electron microscopy (SEM) imaging revealed well-defined microneedles with precise dimensions (800 µm height, 200 µm base and 500 µm pitch). The LMNs rapidly dissolved in the subdermal layer of porcine skin. An ex vivo drug diffusion study showed that 3-5% of the encapsulated lorazepam was released within 30 min, with a cumulative release of 79.3% over 24 h. An acute dermal irritation study confirmed the biocompatibility and skin tolerance of the LMNs. Additionally, an in vivo anti-convulsant efficacy study in Albino Wistar rats subjected to maximal electroshock seizures demonstrated significant anticonvulsant effects (p < .05), confirming efficient systemic delivery of lorazepam. These findings highlight LMNs as a rapid-acting, non-invasive transdermal drug delivery system for managing status epilepticus, particularly in ambulatory care settings.
- 3 April 2025
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (8) , 1399-1411
Design and formulation of fast-dissolving microneedles for the rapid transdermal delivery of lorazepam
This study investigates lorazepam-loaded dissolving microneedles (LMNs) as a fast-acting and minimally invasive treatment for status epilepticus. The LMNs were developed using a micro-moulding technique with an optimised combination of PVP K30, Dextran 40 and Pullulan. Their stability was confirmed through Fourier transform infra-red (FTIR) spectroscopy and X-ray diffraction (XRD) analysis. The Parafilm® membrane insertion test demonstrated 100% penetration efficiency, verifying their ability to effectively pierce the skin. Scanning electron microscopy (SEM) imaging revealed well-defined microneedles with precise dimensions (800 µm height, 200 µm base and 500 µm pitch). The LMNs rapidly dissolved in the subdermal layer of porcine skin. An ex vivo drug diffusion study showed that 3-5% of the encapsulated lorazepam was released within 30 min, with a cumulative release of 79.3% over 24 h. An acute dermal irritation study confirmed the biocompatibility and skin tolerance of the LMNs. Additionally, an in vivo anti-convulsant efficacy study in Albino Wistar rats subjected to maximal electroshock seizures demonstrated significant anticonvulsant effects (p < .05), confirming efficient systemic delivery of lorazepam. These findings highlight LMNs as a rapid-acting, non-invasive transdermal drug delivery system for managing status epilepticus, particularly in ambulatory care settings.
- Open Access
- 1 January 2025
- Published by European Alliance for Innovation n.o.
The Gut-Brain Connection: Exploring the Influence of the Microbiome on Colon Cancer Development and Treatment
The gut-brain axis is an intricate bidirectional communication system between the gastrointestinal tract and the central nervous system that the gut microbiota can commonly influence. Recent studies have shown that the gut microbiome is crucial for colorectal cancer development and progression. The focus is on the close interaction between the gut microbiota and the development of colon cancer by explaining the microbial composition, metabolic byproducts and immune modulation. We also investigated how dysbiosis can promote carcinogenesis through inflammation, genotoxicity and immune evasion. In addition, we consider promising microbiotatargeted therapeutic approaches, such as the use of probiotics and faecal microbiota transplantation, together with the development of biotherapeutics and their ability to improve conventional colon cancer treatments. By elucidating the gut-brain-microbiome interplay, this manuscript aims to provide a comprehensive understanding of its impact on colon cancer, opening new avenues for innovative and effective treatment modalities.
- 1 January 2025
- Published by European Alliance for Innovation n.o.
Open AccessThe Gut-Brain Connection: Exploring the Influence of the Microbiome on Colon Cancer Development and Treatment
The gut-brain axis is an intricate bidirectional communication system between the gastrointestinal tract and the central nervous system that the gut microbiota can commonly influence. Recent studies have shown that the gut microbiome is crucial for colorectal cancer development and progression. The focus is on the close interaction between the gut microbiota and the development of colon cancer by explaining the microbial composition, metabolic byproducts and immune modulation. We also investigated how dysbiosis can promote carcinogenesis through inflammation, genotoxicity and immune evasion. In addition, we consider promising microbiotatargeted therapeutic approaches, such as the use of probiotics and faecal microbiota transplantation, together with the development of biotherapeutics and their ability to improve conventional colon cancer treatments. By elucidating the gut-brain-microbiome interplay, this manuscript aims to provide a comprehensive understanding of its impact on colon cancer, opening new avenues for innovative and effective treatment modalities.
- Open Access
- 1 January 2025
- Published by European Alliance for Innovation n.o.
Recent Discoveries in Breast Cancer: Advancements and Innovations in Diagnosis, Treatment and Management
Breast cancer is still one of the most common causes of cancer deaths in women the world over, even in the face of available treatment and screening methodsThis review article aims to provide the reader with an update on advances in breast cancer with reference to new targets, change in treatment modalities, new developments in diagnosis and approaches to management. This review highlights specific advancements including; liquid biopsy, immunotherapy, biomarkers, and artificial intelligence among others, in the field of breast cancer. Despite the great improvement attained in the previous years in the sphere of personalised approach, questions dealing with heterogeneity of the tumor, issue of treatment refusal, and social disparities requiring improved access to helpful healthcare remain highly debatable. In order, to solve these problems and enhance the outcomes of the diseases, constant research and technical advancements are mandatory to improve patient survival and overall quality of life.
- 1 January 2025
- Published by European Alliance for Innovation n.o.
Open AccessRecent Discoveries in Breast Cancer: Advancements and Innovations in Diagnosis, Treatment and Management
Breast cancer is still one of the most common causes of cancer deaths in women the world over, even in the face of available treatment and screening methodsThis review article aims to provide the reader with an update on advances in breast cancer with reference to new targets, change in treatment modalities, new developments in diagnosis and approaches to management. This review highlights specific advancements including; liquid biopsy, immunotherapy, biomarkers, and artificial intelligence among others, in the field of breast cancer. Despite the great improvement attained in the previous years in the sphere of personalised approach, questions dealing with heterogeneity of the tumor, issue of treatment refusal, and social disparities requiring improved access to helpful healthcare remain highly debatable. In order, to solve these problems and enhance the outcomes of the diseases, constant research and technical advancements are mandatory to improve patient survival and overall quality of life.
- Open Access
- 24 December 2024
- Published by Defence Scientific Information and Documentation Centre in Defence Life Science Journal
- Vol. 10 (1) , 15-22
Poly-Herbal Extract: A Promising Approach for Mitigating Gastric Ulcers in Rat Models
A prevalent condition that affects humans is stomach ulcers. The constraints and rapid expansion of civilization, particularly a stressful lifestyle, are contributing to an increase in the occurrence of ulcers. New synthetic pharmaceuticals and herbal drugs must fulfil global quality, safety, and efficacy criteria as Western medicine progresses. The stomach mucosa breaks down into gastric ulcers, which have a diameter greater than 5 mm and extend into the muscularis mucosa. Changes in the stomach’s defence mechanisms may alter the gastric mucosa, resulting in erosion and ultimately ulceration. This study aims to explore the potential of tamarind seed and aloe vera extracts in mitigating gastric ulcers, presenting a natural alternative to NSAID-induced ulcer treatment. The herbal extract’s effectiveness in reducing oxidative stress and gastric mucosal damage was assessed in comparison to omeprazole. The anti-ulcer activity was assessed using approximated biochemical parameters, and in a dose-dependent manner, the outcomes were statistically noteworthy in contrast to the rats in the ulcer group.
- 24 December 2024
- Published by Defence Scientific Information and Documentation Centre in Defence Life Science Journal
- Vol. 10 (1) , 15-22
Open AccessPoly-Herbal Extract: A Promising Approach for Mitigating Gastric Ulcers in Rat Models
A prevalent condition that affects humans is stomach ulcers. The constraints and rapid expansion of civilization, particularly a stressful lifestyle, are contributing to an increase in the occurrence of ulcers. New synthetic pharmaceuticals and herbal drugs must fulfil global quality, safety, and efficacy criteria as Western medicine progresses. The stomach mucosa breaks down into gastric ulcers, which have a diameter greater than 5 mm and extend into the muscularis mucosa. Changes in the stomach’s defence mechanisms may alter the gastric mucosa, resulting in erosion and ultimately ulceration. This study aims to explore the potential of tamarind seed and aloe vera extracts in mitigating gastric ulcers, presenting a natural alternative to NSAID-induced ulcer treatment. The herbal extract’s effectiveness in reducing oxidative stress and gastric mucosal damage was assessed in comparison to omeprazole. The anti-ulcer activity was assessed using approximated biochemical parameters, and in a dose-dependent manner, the outcomes were statistically noteworthy in contrast to the rats in the ulcer group.
- Open Access
- 24 December 2024
- Published by Defence Scientific Information and Documentation Centre in Defence Life Science Journal
- Vol. 10 (1) , 65-71
A Systemic Review of Beta Caryophyllene
A naturally occurring sesquiterpene known as..........
- 24 December 2024
- Published by Defence Scientific Information and Documentation Centre in Defence Life Science Journal
- Vol. 10 (1) , 65-71
Open AccessA Systemic Review of Beta Caryophyllene
A naturally occurring sesquiterpene known as..........
- Open Access
- 1 October 2024
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 7, 11
Synthesis and evaluation of novel pyrimidine derivative targeting pancreatic adenocarcinoma
Background: Pancreatic adenocarcinoma poses significant challenges in terms of treatment options and prognosis. Novel therapeutic approaches are urgently needed to combat this aggressive form of cancer. The aim of this study is to synthesize and evaluate novel pyrimidine derivatives that can selectively target pancreatic adenocarcinoma cells, providing potential for more effective and less toxic therapeutic options. Methods: This study focuses on the synthesis and evaluation of novel pyrimidine derivatives targeting pancreatic adenocarcinoma. Chalcones were synthesized via Claisen-Schmidt’s condensation reaction using various aromatic aldehydes and ketones under basic conditions. These chalcones were then reacted with guanidine in the presence of basic media and alcohol solvent. The resulting products were purified by neutralization with dilute acid under ice-cold conditions and further purified using column chromatography. The synthesized pyrimidine derivatives were characterized using Fourier-transform infrared (FTIR), nuclear magnetic resonance (NMR), and mass spectrometry. In vitro release characteristics of the conjugates were evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on PanC-1 cell line. Additionally, the therapeutic efficacy of the pyrimidine conjugate was assessed in vivo using Ehrlich ascites carcinoma (EAC) and Dalton’s lymphoma ascites (DLA) cancer cell-induced Swiss albino mice models. Results: The in vitro studies demonstrated that the R2 derivative exhibited strong anticancer activity, with half maximal inhibitory concentration (IC50) values of 52.68 µg/mL against the PanC-1 cell line and 141.387 µg/mL against the MIA PaCa-2 cell line. R1 and R3 showed moderate activity, with IC50 values of 139.7 and 247.11 µg/mL against MIA PaCa-2, respectively. In comparison, 5-fluorouracil (5-FU), a standard chemotherapeutic agent, had an IC50 of 123.33 µg/mL against MIA PaCa-2 but was notably less effective against PanC-1 cells, with an IC50 of 2,166.4 µg/mL. In vivo, the pyrimidine derivatives significantly normalized haematological parameters, restoring red blood cell (RBC), white blood cell (WBC), and haemoglobin levels in cancer-induced mice. Conclusions: The R2 derivative demonstrated significantly enhanced cytotoxicity against pancreatic cancer cells compared to 5-FU, particularly in the PanC-1 cell line, with an IC50 value of 52.68 µg/mL, marking a 95.56% improvement over 5-FU. These results indicate that the synthesized pyrimidine derivatives exhibit promising anticancer activity, warranting further investigation into their clinical application for pancreatic adenocarcinoma treatment.
- 1 October 2024
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 7, 11
Open AccessSynthesis and evaluation of novel pyrimidine derivative targeting pancreatic adenocarcinoma
Background: Pancreatic adenocarcinoma poses significant challenges in terms of treatment options and prognosis. Novel therapeutic approaches are urgently needed to combat this aggressive form of cancer. The aim of this study is to synthesize and evaluate novel pyrimidine derivatives that can selectively target pancreatic adenocarcinoma cells, providing potential for more effective and less toxic therapeutic options. Methods: This study focuses on the synthesis and evaluation of novel pyrimidine derivatives targeting pancreatic adenocarcinoma. Chalcones were synthesized via Claisen-Schmidt’s condensation reaction using various aromatic aldehydes and ketones under basic conditions. These chalcones were then reacted with guanidine in the presence of basic media and alcohol solvent. The resulting products were purified by neutralization with dilute acid under ice-cold conditions and further purified using column chromatography. The synthesized pyrimidine derivatives were characterized using Fourier-transform infrared (FTIR), nuclear magnetic resonance (NMR), and mass spectrometry. In vitro release characteristics of the conjugates were evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on PanC-1 cell line. Additionally, the therapeutic efficacy of the pyrimidine conjugate was assessed in vivo using Ehrlich ascites carcinoma (EAC) and Dalton’s lymphoma ascites (DLA) cancer cell-induced Swiss albino mice models. Results: The in vitro studies demonstrated that the R2 derivative exhibited strong anticancer activity, with half maximal inhibitory concentration (IC50) values of 52.68 µg/mL against the PanC-1 cell line and 141.387 µg/mL against the MIA PaCa-2 cell line. R1 and R3 showed moderate activity, with IC50 values of 139.7 and 247.11 µg/mL against MIA PaCa-2, respectively. In comparison, 5-fluorouracil (5-FU), a standard chemotherapeutic agent, had an IC50 of 123.33 µg/mL against MIA PaCa-2 but was notably less effective against PanC-1 cells, with an IC50 of 2,166.4 µg/mL. In vivo, the pyrimidine derivatives significantly normalized haematological parameters, restoring red blood cell (RBC), white blood cell (WBC), and haemoglobin levels in cancer-induced mice. Conclusions: The R2 derivative demonstrated significantly enhanced cytotoxicity against pancreatic cancer cells compared to 5-FU, particularly in the PanC-1 cell line, with an IC50 value of 52.68 µg/mL, marking a 95.56% improvement over 5-FU. These results indicate that the synthesized pyrimidine derivatives exhibit promising anticancer activity, warranting further investigation into their clinical application for pancreatic adenocarcinoma treatment.
- Open Access
- 17 March 2024
- Published by Brieflands in Journal of Advanced Immunopharmacology
- Vol. 4 (1)
Targeted Molecular Profiling of Non-small Cell Lung Cancer in India
: Cancer often rates highly on lists of the world's most hazardous diseases and routinely appears high on lists of the illnesses that people fear the most. Due of its relevance to the subject at hand, this article concentrates on lung cancer rather than other forms of malignancy. Most patients, both those who have never smoked cigarette as well as those who have, are affected by NSCLC, the more common of these two types. The Mesenchymal – Epithelial Transition (MET) protein amplification, EGFR mutations, RET fusions, and other possible therapeutic targets for the treatment of non-small cell lung cancer are highlighted in this article. The primary aim of this article is to provide a gist of the various mutations and targets' modes of action. It also covers the limits of the medicines that are currently being used to treat certain targets.
- 17 March 2024
- Published by Brieflands in Journal of Advanced Immunopharmacology
- Vol. 4 (1)
Open AccessTargeted Molecular Profiling of Non-small Cell Lung Cancer in India
: Cancer often rates highly on lists of the world's most hazardous diseases and routinely appears high on lists of the illnesses that people fear the most. Due of its relevance to the subject at hand, this article concentrates on lung cancer rather than other forms of malignancy. Most patients, both those who have never smoked cigarette as well as those who have, are affected by NSCLC, the more common of these two types. The Mesenchymal – Epithelial Transition (MET) protein amplification, EGFR mutations, RET fusions, and other possible therapeutic targets for the treatment of non-small cell lung cancer are highlighted in this article. The primary aim of this article is to provide a gist of the various mutations and targets' modes of action. It also covers the limits of the medicines that are currently being used to treat certain targets.
- 18 January 2024
- Published by Springer Nature in Molecular Diversity
- Vol. 28 (6) , 4467-4513
Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship
JAK-STAT signalling pathway was discovered more than quarter century ago. The JAK-STAT pathway protein is considered as one of the crucial hubs for cytokine secretion which mediates activation of different inflammatory, cellular responses and hence involved in different etiological factors. The various etiological factors involved are haematopoiesis, immune fitness, tissue repair, inflammation, apoptosis, and adipogenesis. The presence of the active mutation V617K plays a significant role in the progression of the JAK-STAT pathway-related disease. Consequently, targeting the JAK-STAT pathway could be a promising therapeutic approach for addressing a range of causative factors. In this current review, we provided a comprehensive discussion for the in-detail study of anatomy and physiology of the JAK-STAT pathway which contributes structural domain rearrangement, activation, and negative regulation associated with the downstream signaling pathway, relationship between different cytokines and diseases. This review also discussed the recent development of clinical trial entities. Additionally, this review also provides updates on FDA-approved drugs. In the current investigation, we have classified recently developed small molecule inhibitors of JAK-STAT pathway according to different chemical classes and we emphasized their synthetic routes, biological evaluation, selectivity, and structure–activity relationship. Graphical abstract The JAK-STAT pathway is mainly involved in pathological conditions such as Rheumatoid arthritis, Parkinson’s disease, Atopic dermatitis, Myeloproliferative neoplasm, T-cell leukaemia, Systemic lupus erythematosus, Haematological malignancies, and Idiopathic pulmonary fibrosis. The development of JAK-STAT pathway inhibitors mainly focusses on the inhibition of those diseased conditions. The in-depth review mainly describes the synthetic scheme, structure activity relationship, selectivity and biological activity of globally approved drugs along with recent development of small molecule inhibitors containing different heterocyclic scaffolds (pyridine, pyrimidine, imidazole, indole, pyrazole, pyrrole and triazine).
- 18 January 2024
- Published by Springer Nature in Molecular Diversity
- Vol. 28 (6) , 4467-4513
Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship
JAK-STAT signalling pathway was discovered more than quarter century ago. The JAK-STAT pathway protein is considered as one of the crucial hubs for cytokine secretion which mediates activation of different inflammatory, cellular responses and hence involved in different etiological factors. The various etiological factors involved are haematopoiesis, immune fitness, tissue repair, inflammation, apoptosis, and adipogenesis. The presence of the active mutation V617K plays a significant role in the progression of the JAK-STAT pathway-related disease. Consequently, targeting the JAK-STAT pathway could be a promising therapeutic approach for addressing a range of causative factors. In this current review, we provided a comprehensive discussion for the in-detail study of anatomy and physiology of the JAK-STAT pathway which contributes structural domain rearrangement, activation, and negative regulation associated with the downstream signaling pathway, relationship between different cytokines and diseases. This review also discussed the recent development of clinical trial entities. Additionally, this review also provides updates on FDA-approved drugs. In the current investigation, we have classified recently developed small molecule inhibitors of JAK-STAT pathway according to different chemical classes and we emphasized their synthetic routes, biological evaluation, selectivity, and structure–activity relationship. Graphical abstract The JAK-STAT pathway is mainly involved in pathological conditions such as Rheumatoid arthritis, Parkinson’s disease, Atopic dermatitis, Myeloproliferative neoplasm, T-cell leukaemia, Systemic lupus erythematosus, Haematological malignancies, and Idiopathic pulmonary fibrosis. The development of JAK-STAT pathway inhibitors mainly focusses on the inhibition of those diseased conditions. The in-depth review mainly describes the synthetic scheme, structure activity relationship, selectivity and biological activity of globally approved drugs along with recent development of small molecule inhibitors containing different heterocyclic scaffolds (pyridine, pyrimidine, imidazole, indole, pyrazole, pyrrole and triazine).